Nipin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nipin

Property Description
Active ingredient Nifedipine
Form Oral Capsule or Tablet
Pharmacological class Calcium-channel blocker (Dihydropyridine type)
Origin Synthetic
General purpose To reduce blood pressure and improve cardiac blood flow

Nipin is a pharmaceutical preparation whose sole active ingredient is Nifedipine, a substance designated for oral administration. It is a prescription-only medication classified as a synthetic chemical entity and functions as a single-active ingredient product. Its core composition involves Nifedipine integrated into a suitable inert vehicle for ingestion as either a capsule or a tablet. Nifedipine's precise chemical identity is well-documented, establishing the drug's fundamental structural basis.

Nipin's Pharmacological Class: The Dihydropyridine Type

Nipin belongs to the calcium-channel blocker (CCB) pharmacological class. More specifically, Nifedipine is a dihydropyridine derivative. This classification dictates that the drug's primary action is highly selective toward the smooth muscle of the blood vessels, leading to potent vasodilation (widening of the arteries). This effect is clinically recognized for managing conditions characterized by increased vascular resistance. Its general purpose is thus rooted in its ability to safely and effectively lower arterial pressure, often utilized in scenarios requiring sustained reduction of vascular tone.

Available Forms of Nipin: Capsule versus Tablet

The medication is supplied in distinct dosage forms, notably the immediate-release capsule and the extended-release tablet. The key difference lies in the release rate of Nifedipine once absorbed. The extended-release tablet is engineered to maintain a steady effect over a long period, contrasting with the rapid action profile of the immediate-release capsule. This provides essential flexibility for its general therapeutic application, addressing the distinct needs of patients requiring immediate relief versus those needing long-term stability.

What side effects are possible with Nipin?

Possible Side Effects and Safety Information

The officially documented adverse effects of Nipin (Nifedipine) are classified by frequency and the body system affected, providing a structured understanding of its safety profile as detailed in regulatory documents.

Frequency-Classified Adverse Reactions

Adverse effects are primarily related to the medicine's vasodilatory action and include:

  • Very Common (affecting ge1 in 10 patients): Headache and Oedema (peripheral swelling).
  • Common (affecting ge1 in 100 to <1 in 10 patients): Vasodilatation (flushing) and Constipation.
  • Uncommon (affecting ge1 in 1,000 to <1 in 100 patients): Palpitations, Hypotension, Dizziness, and generalized allergic reactions.

Adverse effects are also documented across various System-Organ Classes, including Nervous System Disorders, Cardiac Disorders, and Gastrointestinal Disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights several serious adverse reactions, which include the rare risk of developing Myocardial Infarction or an increase in the frequency or severity of Angina Pectoris, particularly at the start of treatment or with immediate-release formulations. Excessive Hypotension and severe allergic reactions (such as angioedema) are also documented.

Official safety constraints state that Nipin is contraindicated in Cardiogenic Shock. Use is also restricted in patients taking certain medications, such as strong CYP3A4 inducers (e.g., Rifampin). Furthermore, ingestion of Grapefruit or Grapefruit Juice is explicitly restricted due to the potential for significant increases in drug concentration.


Population and Exposure-Related Safety Notes

The label includes safety considerations for specific groups. Immediate-release Nipin capsules are generally avoided in older adults due to the potential for severe drops in blood pressure. Patients with Hepatic Impairment may require close monitoring. Some side effects, like Gynaecomastia, have been reported with long-term use, while effects like dizziness are noted as more likely during initial dose titration or treatment initiation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Nipin (Nifedipine) is a serious event that mandates immediate medical attention. The officially documented overdose profile is characterized by profound cardiovascular depression, which is an extension of the drug’s intended action as a calcium-channel blocker.

Documented Manifestations and Severe Outcomes

Official regulatory documents state that overdosage may lead to severe hypotension (critically low blood pressure), bradycardia (slow heart rate), and AV node dysfunction. Systemic effects can include disturbances of consciousness, progressing to unconsciousness or coma, as well as hyperglycaemia and metabolic acidosis. Severe outcomes documented in regulatory guidance include cardiogenic shock with pulmonary oedema, which is considered life-threatening.


Emergency Actions and Required Monitoring

Regulatory authorities explicitly mandate that individuals seek immediate medical attention or contact a Poison Control center at once following a suspected or confirmed overdose. Emergency medical care is required, as there is no specific antidote known; management is strictly symptomatic and supportive. Supportive procedures may include the administration of calcium infusions and vasopressors. Hospital monitoring of cardiovascular and respiratory function is mandatory. For sustained-release preparations, regulatory documents specify a minimum hospital observation period of at least 12 hours.

Therapeutic Uses of Nipin

What Nipin treats: main uses and benefits

Nipin (a fictional name for a medicine) is applied across domains where additional symptomatic support is needed, primarily to manage conditions associated with acute or disruptive episodes. Its main use is in providing supportive relief during phases when symptoms become temporarily overwhelming.

Supportive relief is commonly used in settings marked by temporary physiological imbalance, particularly those involving severe or emerging processes.

This medication is relevant for easing a specific cluster of symptoms that may become intense or disruptive. It is commonly used to help with symptoms related to heightened physiological activity, systemic imbalance, and physical discomfort. These are often seen in conditions involving inflammatory or irritative processes, and Nipin is applied in addressing manifestations that interfere with routine activities. It is considered relevant for symptomatic management in situations where patients experience fluctuating manifestations. This supportive approach may help patients cope more steadily with symptom fluctuations.

“Nipin helps maintain a sense of stability when symptoms are more noticeable, contributing to easing the overall symptom load.”

Nipin is generally used for managing symptom clusters that may become intense, disruptive, or suddenly fluctuate, and is applied during phases of increased distress or discomfort.


Quick Fact: Support for Symptom Clusters Nipin supports patients during episodes of heightened discomfort and plays a role in managing symptoms that create noticeable functional strain.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nipin — Official Regulatory Information

Nipin (Nimesulide) is an anti-inflammatory drug with strict regulatory limitations on its use, primarily focused on safeguarding vulnerable populations and individuals with pre-existing organ conditions.


Contraindications and Prohibited Use

Nipin is strictly contraindicated for any individual with a known hypersensitivity or allergy to Nimesulide or any of its excipients.

Use is officially prohibited/banned for all children under 12 years of age and is not recommended for adolescents under 18 years.


Restricted and Not Recommended Use

Official documents strongly recommend against the use of Nipin in several clinical populations due to increased risk:

  • Hepatic Impairment: Individuals with severe liver disease or significant hepatic impairment.
  • Renal Impairment: Individuals with severe kidney disease.
  • Gastrointestinal Conditions: Patients with an active stomach ulcer, recent gastrointestinal bleeding, or a history of severe GI issues.
  • Cardiac/Circulatory States: Individuals with severe heart disease or coagulation disorders.
  • Physiological States: Pregnant and nursing mothers are advised against use, as it may affect fertility and can pass into breast milk.

Use of Nipin is generally restricted to the adult population that does not present with these specific pre-existing conditions or physiological states.

What should I know about interactions with other medicines?

The official interaction profile for Nipin (Nifedipine) is primarily defined by its extensive metabolism via the Cytochrome P450 3A4 (CYP3A4) enzyme system. This leads to two major pharmacokinetic patterns: substances that inhibit CYP3A4, which increases Nipin's plasma concentrations, and substances that induce CYP3A4, which significantly reduces Nipin's systemic exposure and efficacy.

Formal Regulatory Constraints and Exposure Modifiers

Classification Interacting Agents (Examples) Official Effect
Contraindicated Rifampicin, St. John's Wort Substantial loss of Nipin efficacy (via CYP3A4 induction)
Increased Exposure Azole Antifungals, Macrolides, HIV Protease Inhibitors Potential for increased Nipin effects (via CYP3A4 inhibition)
Additive Effect Beta-blockers, Other Antihypertensives Risk of excessive blood pressure lowering (pharmacodynamic)

Additionally, regulatory labeling mandates the avoidance of Grapefruit or Grapefruit Juice due to its potential to double Nipin's plasma concentration. A specific timing constraint is noted for High-Dose Fentanyl administration in a surgical context, suggesting the drug may be withheld for at least 36 hours prior, if conditions allow. The profile includes a caution for patients with hepatic impairment, as decreased drug clearance in this population may alter the interaction profile and drug effects.

Mechanism of Action

Nipin's mechanism of action is defined by targeted enzyme inhibition that modifies key cellular signaling pathways, leading to an altered physiological state.


Cyclooxygenase (COX) Enzyme Inhibition

Nipin acts within domains involving enzyme-mediated signaling by directly inhibiting the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This interaction modifies the initial steps in the arachidonic acid cascade, which is the primary pathway for the cellular production of eicosanoid mediators.


Impact on Eicosanoid-Driven Signaling

Suppression of eicosanoid synthesis impacts intracellular pathways where these mediators are highly active. This mechanistic cascade results in the reduction of local and systemic concentrations of pro-inflammatory eicosanoids. The resulting physiological effect is a quantifiable decrease in eicosanoid-driven signaling intensity, altering the local cellular environment.


Downstream Cellular Effects

By decreasing eicosanoid concentrations, Nipin alters the signaling equilibrium within affected cellular systems. This pathway modification is observed in cells characterized by high eicosanoid turnover, resulting in modified feedback regulation within the targeted biochemical processes.

Dosage and Administration Information

How Nipin is Used: Official Administration Guidelines

Nipin (Nifedipine) is administered strictly via the oral route and is available in two main forms: the Immediate-Release (IR) capsule and the Extended-Release (ER) tablet. The distinct forms dictate the dosing frequency and handling constraints, which are specified in official prescribing information.


Official Dosing and Frequency Patterns

Administration Pattern Immediate-Release (IR) Capsule Extended-Release (ER) Tablet
Dosing Frequency Typically multiple times a day (e.g., three or four times daily). Typically once daily at a consistent time.
Starting Dose Typically 10 mg three times a day. Typically 30 mg or 60 mg once daily.
Adjustment Period Dose titration is conducted gradually over 7 to 14 days. Dose titration is conducted gradually over 7 to 14 days.

Administration Requirements and Handling

Administration of Nipin requires adherence to specific instructions to ensure the correct delivery of the active ingredient:

  • ER Tablet Integrity: The Extended-Release tablets must be swallowed whole and must not be crushed, chewed, or divided under any circumstances, as this disrupts the controlled-release mechanism.
  • Food Intake: The IR capsule may be taken with or without food. However, certain ER formulations are intended to be taken on an empty stomach. All patients must strictly avoid grapefruit and grapefruit juice.
  • Population Adjustments: Use of IR capsules is generally avoided in older adults due to reduced clearance. Patients with severe hepatic impairment may require careful monitoring and a dose reduction.

Treatment with Nipin is generally intended for long-term use and should be discontinued only by gradually tapering the dose under appropriate supervision.

Recent Clinical Evidence

Research evidence / Overview of Studies for Nipin


Evidence for Use in Hypertension (High Blood Pressure)

Research for Nipin in hypertension, or high blood pressure, includes large-scale Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These trials were primarily conducted in adults with essential hypertension. Researchers monitored study participants over defined time intervals to measure changes in systolic and diastolic blood pressure readings. The studies also examined cardiovascular outcomes, such as the rates of serious events.

Findings describe the patterns of blood pressure changes observed in the studied groups, generally reporting outcomes related to blood pressure levels across various adult populations. Longer-term studies reported how the rates of cardiovascular events, like heart attack and stroke, were monitored over periods lasting several years in patients studied. The extended-release or sustained-release forms are the focus of most current long-term research.

Evidence for Use in Chronic Stable Angina Pectoris

The research for Nipin in chronic stable angina pectoris includes numerous Randomized Controlled Trials (RCTs) and subsequent Meta-analyses. These studies were conducted primarily in adults who experience stable, effort-induced chest pain. Studies focused on outcomes capturing phases of heightened symptom activity, mainly by measuring the frequency of angina attacks and documenting changes in a patient's exercise tolerance in controlled settings.

In these trials, findings describe patterns observed, such as the measured frequency of angina episodes in the study populations. Research also monitored outcomes related to patient-reported experiences, tracking the need for rescue medication use over defined time intervals. These studies contribute to understanding symptom patterns.

Evidence Gaps and Areas of Uncertainty

Research highlights what is known, but evidence also indicates what is still uncertain. One key limitation is the continuing need for more head-to-head comparative evidence between the various long-acting Nipin formulations and other established first-line treatments for high blood pressure. Data for certain subgroups, particularly those with rare or complex heart and kidney comorbidities, remain insufficient. Regarding long-term outcomes, while research does describe patterns of cardiovascular event rates over several years, the long-term effects are not fully established for every single formulation and dosing strategy. For less-studied contexts, follow-up durations were limited.

Frequently Asked Questions (FAQ)

Common questions about Nipin (FAQ)


Q: How long does the effect of a single dose of Nipin last?

The length of time Nipin's effects last depends on the form taken. The extended-release tablet is specially designed to release the drug steadily over an approximately 24-hour period. Official documents state that the half-life—the time for the drug's concentration to fall by half—is approximately seven hours for the extended-release form and two hours for the immediate-release capsule.


Q: Does Nipin contain any ingredients that cause allergic reactions?

Like most medicines, Nipin contains both the active ingredient, nifedipine, and non-active ingredients called excipients. Official safety information indicates that if you have any known allergies, especially to inactive ingredients in medicines, this should be discussed with a healthcare provider. Some formulations may contain specific color additives that can cause allergic reactions in sensitive individuals.


Q: Is Nipin safe to take with common over-the-counter pain relievers?

The official interaction profile for Nipin is complex, and many other medicines may influence how it works. Regulatory guidance emphasizes telling your healthcare provider about all medicines you are taking, including any over-the-counter pain relievers or cold remedies. This is to help mitigate the risk that Nipin's blood levels are unintentionally altered.


Q: Are there any specific vitamins or supplements that interact with Nipin?

Yes, the use of certain herbal or non-prescription supplements may affect the way Nipin works. Official patient labeling specifically mentions that the herbal product St. John's wort is known to interact. Official guidance emphasizes that all supplements should be disclosed to a healthcare provider to help evaluate potential interaction concerns.


Q: Can Nipin be used safely by older adults (e.g., over 65)?

Official documents indicate that caution is advised when Nipin is used in older adults. Specifically, the immediate-release capsule formulation is generally avoided in this population. This is due to potential safety concerns, such as the risk of excessive blood pressure lowering.


Q: Can Nipin affect my ability to drive or operate machinery?

Yes, official warnings note that Nipin may cause side effects like drowsiness and dizziness, particularly when first starting treatment. Regulatory guidance advises that activities requiring mental alertness, such as driving, should be avoided until an individual understands how Nipin affects them.


Q: Does the time of day matter when taking Nipin?

For the extended-release formulation, regulatory literature indicates that consistent timing is important to maintain stable effects. Some studies referenced in regulatory data suggest that taking the once-daily extended-release dose at bedtime may be associated with increased blood pressure control, especially during the nighttime hours.


Q: How quickly does Nipin usually start to work?

The speed at which Nipin begins to work depends on its specific formulation. Official pharmacokinetics data shows that the extended-release tablet typically begins to reach its initial peak concentration in the bloodstream between 2.5 and 5 hours after it is taken. The immediate-release capsule is designed to act more rapidly, though its specific time-to-effect is not consistently detailed in patient labeling.


Q: Why do some people say Nipin makes them feel tired?

Fatigue and unusual tiredness are noted as reported adverse effects in the official safety information for Nipin. If this effect is experienced, it is described as a potential side effect of the medicine.


Q: Is it common to have stomach upset when first taking Nipin?

Yes, regulatory safety information lists nausea, vomiting, and stomach pain among the reported adverse effects. Patients should also be aware that, in rare cases, the extended-release tablet has been associated with more serious gastrointestinal issues, such as stomach obstruction.


Q: Does Nipin interact with birth control pills?

Official patient information indicates that Nipin (nifedipine) does not affect the efficacy of hormonal contraceptives, such as birth control pills. However, high blood pressure itself is a condition that may sometimes affect the choice of a specific contraceptive method.


Q: Is it okay to drink coffee or caffeine while taking Nipin?

While there is no strict regulatory restriction on coffee or caffeine intake comparable to the warning against grapefruit, caution is advised. Nipin is intended to lower blood pressure, and some research suggests that consuming caffeine may counteract the medication's full pressure-lowering effect. Official guidance indicates that caffeine intake is an element that should be discussed with a healthcare professional.


Q: What happens if I miss a dose of Nipin?

Official patient instructions for a missed dose advise taking the dose as soon as you remember. However, if it is nearly time for the next scheduled dose, the instructions state to skip the missed dose entirely and continue with the regular schedule. Official instructions state that patients should not take a double or extra dose to compensate for the missed one.


Q: Does Nipin cause weight gain or weight loss?

Official safety information does not list significant weight change as a common side effect. However, unusual weight gain is specifically noted, along with swelling (oedema), as a symptom that official safety information indicates should be reported to a healthcare provider for monitoring.


Q: Is Nipin available as a generic medicine?

Yes, official FDA records confirm that generic versions of the active ingredient, nifedipine, are available in both capsule and extended-release tablet forms.


Q: How long after stopping Nipin does it stay in your system?

The length of time Nipin remains in your system relates to its half-life, which is the time it takes for the concentration to reduce by half. The half-life for the immediate-release form is approximately two hours, and for the extended-release form, it is about seven hours. The medication will take several half-lives to be fully cleared from the body.


Q: Is Nipin known to cause mood changes or depression?

Official safety information lists mood changes among the reported side effects of Nipin, although they are noted to be less common. Patients are advised to be aware of the possibility of such changes while using the medication.


Q: Is Nipin available in different strengths?

Yes, the official prescribing information shows that the extended-release tablets are available in several strengths for once-daily use. These typically include 30 mg, 60 mg, and 90 mg tablets.


Q: Why is it important to complete the full course of Nipin as prescribed?

Regulatory patient guidance emphasizes that Nipin is prescribed to manage a chronic condition, such as high blood pressure, and is not a cure. Therefore, it is important to continue taking the medication exactly as directed, even if you begin to feel well. Regulatory patient guidance indicates that treatment discontinuation is intended to occur gradually and under appropriate medical supervision.


Q: Does Nipin have a black box warning from the FDA?

Yes, the immediate-release capsule formulation of Nipin carries a Black Box Warning from the FDA. This is the strictest safety warning. This warning relates to the risk of serious adverse cardiovascular events when the immediate-release capsule is used in high-risk, acute settings.


Q: How do I know if the side effects I am having are serious?

Official patient safety information provides a list of symptoms that are considered signs of serious adverse reactions. These include excessive drops in blood pressure, fainting, chest pain, and severe swelling of the face or throat. Official regulatory patient safety information indicates that if these severe symptoms occur, emergency medical attention should be sought.


Q: Is Nipin a controlled substance?

No, official regulatory scheduling information states that Nipin, which is nifedipine, is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA).

How should Nipin be stored and disposed of?

Official Storage Conditions

Scope Item Official Regulatory Statement
Temperature Requirements Capsules: Store at 20^circC to 25^circC (68^circF to 77^circF). Tablets: Store below 30^circC (86^circF).
Protection Requirements Must be kept protected from light and away from excess moisture.
Container Rules Must be kept in the original container, tightly closed, and must not be frozen.
Child Safety Must be stored out of the sight and reach of children; use locked safety caps.

Official Disposal Rules

The primary method for discarding unused Nipin is through an official drug take-back program or an authorized collector. If a take-back option is unavailable, the medication should not be flushed. Instead, it must be removed from its container, mixed with an undesirable substance like coffee grounds or cat litter, sealed in a bag or container, and disposed of in the household trash. Personal information on the prescription label must be removed or scratched out prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nipin found in:

A-Z Index: